References
- 1. Oellerich M., Amstrong VW. & Kahan B. et al. (1995) Lake Louise consensus conference on cyclosporin monitoring in organ transplantation: report of consensus panel, Ther Drug Monit. 17, 642-654
- 2. Kahan BD., Shaw LM. & Hold D. et al. (1990) Consensus document: Haw’s Cay meting on therapeutic drug monitoring of cyclosporine, Clin Chem. 36, 1510-6
- 3. Levey AS., Coresh J., Greene T., Stevens LA., Zhang YL. & Hendriksen S., et al. (2006). Chronic Kidney Disease Epidemiology Collaboration. Using standardized serum creatinine values in the Modification of Diet in Renal Disease study equation for estimating glomerular filtration rate. Ann Intern Med. 145(4), 247-254.
- 4. Miller WG. (2011). Glomerular Filtration Rate. The Importance of Standardized Serum Creatinine in Detecting Kidney Disease. ClinicalLaboratory News. 37(12), 10-12.
- 5. Marqut P., Leger F., Pisano P. & Billaud EM. (2004). Suivi thérapeutique de la ciclosporineIn Suivi thérapeutique pharmacologique pourl’adaptation de posologie des médicaments, (pp 280-293). Paris: Elsevier
- 6. Tedesco D. & Haragsim L. (2012). Cyclosporine: A Review, Journal of Transplantation, Article ID 230386, 7 pages. DOI:10.1155/2012/230386
- 7. Martins L., Ventura A. & Branco A. et al. (2004). Cyclosporine versus tacrolimus in kidney transplantation: are there differences in nephrotoxicity? Transplant Proc. 36(4), 877-879.
- 8. Ojo AO., Held P.J. & Port F.K. et al. (2003). Chronic renal failure after transplantation of a nonrenal organ. The New England Journal ofMedicine. 349(10), 931-940
- 9. Ispas M., Chincisan C., Voidăzan S., Mărginean A. & Dobreanu M. (2012). Chronic kidney disease after treatment with cyclosporine or tacrolimus in heart transplant recipients - experience of a Romanian medical center. Revista Română deMedicină de Laborator. 20(2/4), 117-125
- 10. Castel M.A., Farrero M., Vallejos I., Cardona M., Regueiro A. & Pérez-Villa F. (2011). Primary immunosuppression and outcome differences after heart transplantation: tacrolimus versus cyclosporine. Transplant Proc. 43(6), 2244-6
- 11. Meiser B.M., Groetzner J. & Kaczmarek I. et al (2004). Tacrolimus or cyclosporine: which is the better partner for mycophenolate mofetil in heart transplant recipients? Transplantation. 78(4), 591-8.
- 12 Baran D.A., Zucker M.J. & Arroyo L.H. et al. (2011). A prospective, randomized trial of singledrug versus dual-drug immunosuppression in heart transplantation: the tacrolimus in combination, tacrolimus alone compared (TICTAC) trial. Circ Heart Fail. 4(2), 129-37
- 13. Kobashigawa J.A. (2011). Strategies in immunosuppression after heart transplantation: is less better? Circ Heart Fail. 4(2), 111-3
- 14. Garlicki M. (2005). Post-transplant diabetes mellitus (PTDM) in heart recipients, AnnTransplant. 10(3), 51-3
- 15. Simmonds J., Dewar C., Dawkins H., Burch M. & Fenton M. (2009). Tacrolimus in pediatric heart transplantation: ameliorated side effects in the steroid-free, statin era. Clin Transplant. 23(3), 415-419
- 16. Morales J.M., Andrés A. & Dominguez-Gil B. et al. (2005). Ten years of treatment with tacrolimus is related to an excellent renal function, allowing monotherapy in a large proportion of cases: unicentric results of the tacrolimus versus cyclosporine. A European multicentric study in kidney. Transplantation Proceedings. 37(9), 3738-3742